The AMPs in a mixed peptide showed promising use as a surface therapy and inhibited skin infections caused by Enterococcus faecium, Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumonia and Acenetobacter baumanni. The gene discussed is ADSL; the disease is skin infection.